MBX Biosciences, Inc. Common Stock

MBX trades at just $1.5B market cap while carrying 12.63% short interest—a notable bearish bet that contrasts with the stock's neutral RSI of 46.1, suggesting no extreme momentum either direction. The absence of a P/E ratio signals the company remains unprofitable, which aligns with early-stage biotech dynamics where value hinges entirely on pipeline catalysts rather than earnings power. Trading well below its 52-week high leaves room for upside if clinical data or regulatory milestones materialize, though the substantial short position indicates meaningful skepticism about near-term execution. This setup resembles classic biotech risk—binary event-driven with asymmetric payoff potential but significant downside vulnerability.